non-coding RNA
One independent researcher called the study "a valuable guide for experimental validation of circRNAs" in cancer and neurodegenerative disease research.
Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial
The collaborators are using Exai's oncRNA-based liquid biopsy tech in predicting clinical outcomes and treatment response in the I-SPY 2 trial.
The company is assessing a variety of applications, including cancer early detection, using algorithms to analyze orphan noncoding RNA in blood.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.